Starboard has a $1 billion stake in Pfizer and an unknown but "sizable" stake in Kenvue, according to earlier media reports.
In the assessment of 12-month price targets, analysts unveil insights for Kenvue, presenting an average target of $24.1, a ...
Starboard Chief Executive Jeff Smith said that Kenvue, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment, which he ...
Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its ...
BofA raised the firm’s price target on Kenvue (KVUE) to $27 from $24 and keeps a Buy rating on the shares. Noting that The Wall Street ...
Kenvue shares jumped premarket after The Wall Street Journal reported that Starboard Value has taken a sizable stake in the ...
Activist investor Starboard Value reportedly has taken a large stake in consumer health products maker Kenvue.
Kenvue, Inc. (KVUE – Research Report), the Technology sector company, was revisited by a Wall Street analyst yesterday. Analyst Anna ...
Financial writer highlights activist investor Starboard Value's push for Kenvue (KVUE) to divest its challenged skin, ...
Kenvue is a consumer products company that spun off from Johnson & Johnson in 2023. The split from Johnson & Johnson ( JNJ) ...
Recent health news includes a court ruling allowing Amgen's Eylea biosimilar launch, Starboard criticizing Kenvue's skin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback